Sign in →

Test ID: CSTB CSTB Gene, Repeat Expansion Analysis, Varies


Ordering Guidance


This test only detects dodecamer repeat expansions. If testing for both dodecamer repeat expansions and other CSTB variants is requested, order a custom gene panel for the CSTB gene. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated


Forms

1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing  (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Molecular Genetics: Neurology Patient Information

3. If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.

Useful For

Molecular confirmation of clinically suspected CSTB-related progressive myoclonic epilepsy

 

Identifying full penetrance dodecamer repeat expansions within CSTB known to cause CSTB-related progressive myoclonic epilepsy, allowing for predictive testing of at-risk family members

 

Impacting patient treatment and management through the identification of a specific underlying etiology for epilepsy (eg, directing appropriate use of anti-epileptic drugs and other treatment modalities)

Genetics Test Information

This test assesses for CCC-CGC-CCC-GCG dodecamer repeat expansions in the promoter region of CSTB to confirm a molecular diagnosis of CSTB-related progressive myoclonic epilepsy, also known as progressive myoclonic epilepsy type 1 (EPM1).

Method Name

Polymerase Chain Reaction (PCR)

Reporting Name

CSTB, Repeat Expansion Analysis

Specimen Type

Varies

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
  Frozen 
  Refrigerated 

Clinical Information

CSTB-related progressive myoclonic epilepsy (PME), also known as progressive myoclonic epilepsy type 1 (EPM1) or Unverricht-Lundborg disease, is the most common and least severe of the collective progressive myoclonic epilepsies. CSTB-related PME is inherited in an autosomal recessive pattern and is associated with inter- and intrafamilial variability. Individuals with CSTB-related PME have normal early development with onset of symptoms typically in the first or second decade of life. CSTB-related PME is characterized by involuntary myoclonus that is action- or stimulus-precipitated. Individuals with the condition are at increased risk for seizures, including tonic-clonic, absence, psychomotor and focal motor. The condition is progressive, leading to wheelchair dependence in some individuals. Later symptoms may also include ataxia, incoordination, intention tremor, dysarthria, mood disorders, and mild cognitive decline.

 

CSTB-related PME is caused by disease-causing variants in the CSTB gene. An expansion of a dodecamer repeat sequence in the promoter region of the CSTB gene accounts for approximately 90% of disease-causing variants (99% in Finnish individuals). Full penetrance CSTB expansions are greater than or equal to 30 repeats, while normal alleles are typically 2 or 3 repeats. Allele sizes between 5 and 29 repeats are of unclear significance. The remainder of disease-causing variants are sequence variants including missense, nonsense, splice site variants, and small deletions and duplications. Genotype/phenotype correlation suggests that individuals who are homozygous for nonexpansion variants or compound heterozygous for one expansion allele and one nonexpansion allele have earlier onset and more severe symptoms than those individuals with biallelic expansion alleles. Instability of the repeat expansion has been reported with vertical transmission, including both minimal expansion and contraction of repeat sizes. Alleles in the uncertain range are not associated with symptoms of CSTB-related PME but may demonstrate instability with transmission. Since repeat alleles in this size range have rarely been reported, the risk of repeat expansion into the full penetrance allele range (>29 repeats) is not fully understood. Additionally, correlation of repeat size with onset of symptoms is unclear.

Reference Values

Normal: <5 dodecamer repeats

Repeat Size of Uncertain Significance: 5-29 dodecamer repeats

Full Penetrance Expansion: >29 dodecamer repeats

An interpretive report will be provided.

Interpretation

An interpretive report will be provided.

 

Clinical Reference

1. Lehesjoki AE, Koskimiemi M: Progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia. 1999;40 Suppl 3:23-28

2. Hypponen J, Aikia M, Joensuu T, et al: Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study. Neurology. 2015 Apr 14;84(15):1529-1536

3. Canafoglia L, Gennaro E, Capovilla G, et al: Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations. Epilepsia. 2012 Dec;53(12):2120-2127

Day(s) Performed

Varies

Report Available

28 to 42 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81188

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CSTB CSTB, Repeat Expansion Analysis 41110-8

 

Result ID Test Result Name Result LOINC Value
616516 Result Summary 50397-9
616517 Result 82939-0
616518 Interpretation 69047-9
616519 Reason for Referral 42349-1
616520 Specimen 31208-2
616521 Method 85069-3
616522 Source 31208-2
616523 Released By 18771-6

Testing Algorithm

For more information see Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm

Mayo Clinic Laboratories | Genetics and Genomics Additional Information:

mcl-moltechtestmenu; mcl-neurology